{"disease":{"id":"advanced-hepatocellular-carcinoma","name":"Advanced Hepatocellular Carcinoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":1,"trial_count":11},"drugs":{"marketed":[],"pipeline":[{"drug_id":"pd-0332991","indication_name":"Advanced Hepatocellular Carcinoma","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PD-0332991","generic_name":"pd-0332991","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase TAO2","drug_class":"PD-0332991, 125mg, 3 cycles","quality_score":null,"revenue":null,"mechanism":"PD-0332991, 125mg, 3 cycles"}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT06618664","title":"Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT04523493","title":"Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":530,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT06644430","title":"Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":470,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04576572","title":"Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":424,"lead_sponsor_name":"Inonu University","has_results":false},{"nct_id":"NCT06427941","title":"A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":392,"lead_sponsor_name":"BeOne Medicines","has_results":false},{"nct_id":"NCT05824975","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT01015833","title":"Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":356,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01829035","title":"A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":339,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT03905967","title":"TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":336,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04723004","title":"Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":326,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT03236636","title":"The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":312,"lead_sponsor_name":"Beijing Shenogen Biomedical Co., Ltd","has_results":false},{"nct_id":"NCT06434753","title":"Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Hospital Universitari Vall d'Hebron Research Institute","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06323382","title":"Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07166406","title":"Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":226,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07275073","title":"JMT106 Injection in the Treatment of Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT05738616","title":"Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":196,"lead_sponsor_name":"Wen Tianfu","has_results":false},{"nct_id":"NCT07583316","title":"A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":192,"lead_sponsor_name":"Corregene Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT04242199","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT01033240","title":"CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":172,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT07197554","title":"A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":171,"lead_sponsor_name":"SEED Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02528643","title":"A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT04157985","title":"Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Dan Zandberg","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT06600321","title":"A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":158,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT07147101","title":"Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04374877","title":"Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":145,"lead_sponsor_name":"Coherus Oncology, Inc.","has_results":false},{"nct_id":"NCT07227012","title":"Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":138,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04862949","title":"Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC","phase":"","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"CHA University","has_results":true},{"nct_id":"NCT05444088","title":"Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":129,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT06828380","title":"A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT02834780","title":"Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"H3 Biomedicine Inc.","has_results":true},{"nct_id":"NCT06362369","title":"A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"7 Hills Pharma, LLC","has_results":false},{"nct_id":"NCT04183088","title":"Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":125,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT05168163","title":"Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":122,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT04740307","title":"Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07282509","title":"Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":116,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT05883644","title":"Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":111,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05377034","title":"Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"National Cancer Centre, Singapore","has_results":false},{"nct_id":"NCT06873269","title":"Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Universitair Ziekenhuis Brussel","has_results":false},{"nct_id":"NCT05173298","title":"Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"CHA University","has_results":false},{"nct_id":"NCT04730388","title":"ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT02082210","title":"A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT04401813","title":"Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT04948697","title":"A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT03684811","title":"A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Forma Therapeutics, Inc.","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}